End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

BACKGROUND: Previous analyses from a randomised trial in women aged 24–45 years have shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN), and external genital lesions (EGLs) related to HPV 6/11/16/18. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Castellsagué, X, Muñoz, N, Pitisuttithum, P, Ferris, D, Monsonego, J, Ault, K, Luna, J, Myers, E, Mallary, S, Bautista, O M, Bryan, J, Vuocolo, S, Haupt, R M, Saah, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137403/
https://www.ncbi.nlm.nih.gov/pubmed/21629249
http://dx.doi.org/10.1038/bjc.2011.185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137403/
https://www.ncbi.nlm.nih.gov/pubmed/21629249
http://dx.doi.org/10.1038/bjc.2011.185

Ejemplares similares